Weekly Reads: $1B+ Neurona Acquisition, Cells + Organs = Better Transplant?, DAXX in Germ Cells, KRAS
UCB announced a strategic acquisition of Neurona Therapeutics for over $1 billion, including a $650 million cash payment. The deal brings Neurona’s lead cell‑therapy candidate NRTX‑1001, a line of engineered inhibitory interneurons targeting drug‑resistant epilepsy, into UCB’s pipeline. The acquisition signals UCB’s deeper entry into regenerative medicine and expands its neurology portfolio. Parallel advances in cell‑based organ‑transplant tolerance and KRAS‑targeted oncology underscore a broader shift toward precision biologics.
Parkinson's Disease
A recent randomized controlled trial found that daily resistant starch supplementation alleviated motor symptoms in Parkinson’s disease patients. Over a 12‑week period, participants showed a 15% reduction in Unified Parkinson’s Disease Rating Scale (UPDRS) motor scores compared with placebo. The...
HIV Medication Reverses Epigenetic Aging Markers in First Human Proof-of-Concept Trial
A proof‑of‑concept trial found that the HIV pre‑exposure drug FTC/TAF (Descovy) significantly reduced several epigenetic aging clocks in healthy adults, with declines of up to 3.4 years in heart, brain and metabolic markers. The molecular data showed an improved immune...
Artificial Intelligence and Evidence-Informed Policy: Emerging Challenges and Opportunities
The World Health Organization released a discussion paper on the convergence of artificial intelligence (AI) and evidence‑informed policy‑making (EIP) in health. It outlines how AI can accelerate data integration, predictive modelling, scenario simulation and adaptive feedback throughout the policy cycle....
How Blood-Based Brain Biomarkers Predict Alzheimer’s Progression
Recent research highlights plasma phosphorylated tau217 (p‑tau217) as the most accurate blood‑based marker for forecasting Alzheimer’s disease, achieving up to 96% diagnostic precision. Elevated p‑tau217, together with GFAP, neurofilament light chain and low amyloid‑beta ratios, predicts incident dementia, while obesity...
Dr. William Makis: Doctors Offer EUTHANASIA to COVID Jab Victims—“They Don’t Want Anything to Do With You”
Dr. William Makis, a Canadian oncologist now based in Florida, claims that patients who suffer injuries they attribute to COVID‑19 vaccines are being denied proper medical care and are instead offered medically assisted suicide in Canada. He cites a case...
AI Helps Chemists Design Molecules Step by Step
Researchers at EPFL unveiled Synthegy, a new framework that pairs large language models with traditional retrosynthesis and mechanism‑prediction tools. By translating candidate pathways into text, the LLM evaluates each route against plain‑language user goals and scores its chemical plausibility. In...
Why Local Care Matters for Peripheral Arterial Disease
Peripheral arterial disease (PAD) remains a leading cause of stroke, amputation and death, affecting more than 200 million people worldwide. Dr. Devin Zarkowsky argues that delivering PAD care locally—through office‑based procedures, portable imaging and minimally invasive techniques—dramatically improves outcomes and reduces...
Capitol Dispatch Weekend Digest
The Connecticut Senate approved a bill prohibiting private‑equity firms from acquiring or expanding control of state hospitals, effective October 2026. Simultaneously, the state’s insurance regulator fined the five largest health insurers for breaching mental‑health parity requirements. The state agricultural lab...
Medicare Practice Expense Cuts Will Hurt Patients
The Centers for Medicare & Medicaid Services released a final rule for the 2026 Medicare Physician Fee Schedule that trims practice‑expense inputs, lowering facility‑based physician payments by about 7%. The reduction does not reflect the true overhead costs independent clinicians...
CMS Posts January 2026 Medicaid/CHIP Enrollment Report: 75.3M, Down 4.2M Since December 2024
The Centers for Medicare & Medicaid Services released its January 2026 Medicaid and CHIP enrollment snapshot, showing 75.3 million total enrollees – 68.0 million in Medicaid and 7.2 million in CHIP. Adult Medicaid coverage accounts for 39.4 million, while children and CHIP participants total 35.9 million....
Congress Stalls, Xylazine Spreads
Xylazine, a veterinary sedative, remains unscheduled under the Controlled Substances Act, allowing unrestricted importation despite its presence in roughly 25% of the U.S. fentanyl supply and its link to thousands of preventable amputations each year. The DEA has detected the...
We’re Prescribing the Wrong First Treatment
The article argues that exercise is an underused first‑line treatment for teen depression, performing on par with antidepressants in many studies. Landmark trials like the SMILE study and a 2024 BMJ meta‑analysis show comparable remission rates and lower relapse when...
I Was Treated for Tuberculosis While Millions Were Robbed of Care
The author recounts a personal encounter with tuberculosis after a positive test in March 2025, following immunosuppressive treatment for arthritis. She reflects on historical TB care, noting 1930s practices of treating patients outdoors on iron beds, and contrasts that with...
I Test for 50+ Cancers Every Year. Here's What's Actually Worth It.
Multi‑Cancer Early Detection (MCED) blood tests now screen for 50+ cancers in a single annual draw, promising earlier diagnosis than traditional organ‑specific screens. The FDA‑cleared Galleri test leads the market, showing about 70% sensitivity for early‑stage disease but also a...
What Does 17 Pharma MFN Deals Are Underneath the Press Releases: The Real Primary Source Stack, the GLP1 Numbers, TrumpRX...
A White House‑driven most‑favored‑nation (MFN) pricing initiative has secured agreements with 17 major pharmaceutical companies, representing roughly 86% of the U.S. branded drug market. The deals, reconstructed from demand letters, rolling announcements and third‑party reports, lock Medicaid and direct‑to‑consumer (TrumpRx)...
What If Fourteen Risk Factors Explained Nearly Half of All Dementia, and You Could Change Every One?
A 2024 international commission report found that 45% of global dementia cases are linked to 14 modifiable risk factors, up from 40% in the 2020 review. The updated list adds high LDL cholesterol and untreated vision loss and emphasizes that...
Obesity Treatment: Still Judging After All These Years
A new study in Scientific Reports surveyed roughly 1,200 adults in the United States, United Kingdom and Belgium to examine how people judge individuals who lose weight with GLP‑1 obesity medicines versus lifestyle changes alone. Participants perceived medication‑assisted weight loss...
Chemical Frontiers: The Hidden Risks of the Psychedelic Renaissance
On April 18, President Donald Trump signed an executive order to accelerate the development of psychedelic medicines. The order directs the FDA to give expedited review to qualifying psychedelic drugs and instructs the Department of Health and Human Services to...
What Exactly Is Health?
The ongoing NHS doctor strike has spotlighted deep‑seated tensions within Britain’s health system, prompting a broader debate about what health truly means. Mark Vernon, drawing on his experience as a psychotherapist in a psychiatric hospital, argues that genuine listening can...
Can Corpus Replace Health Insurance
Health insurers in India paid roughly ₹32,000 crore ($3.9 bn) on 6.2 million claims in FY25, showing that the industry does settle the majority of claims despite a noisy trust deficit. The author argues that a personal savings corpus cannot replace a renewable...
Trump Administration Seeks Pause Of Lawsuit Challenging Vaccine Recommendations
On April 23, Trump administration lawyers filed a motion asking U.S. District Judge Brian Murphy to pause litigation that challenges recent CDC vaccine guidance updates made under Health Secretary Robert F. Kennedy Jr. The request argues that a stay pending...
FDA Grants Quick Review Psychedelic Drugs, First Approvals Could Come As Soon As Summer
The FDA announced an accelerated review pathway for psychedelic therapies, aiming to clear the first approval by the end of summer. The move follows President Trump’s executive order, which allocates $50 million for state‑level research partnerships and directs faster rescheduling of...
NO JAB, NO PAY/PLAY BILL COMING
New South Wales Libertarian MLC John Ruddick is drafting a bill to block the state’s “No Jab, No Pay/Play” policy, which ties family tax benefits and childcare subsidies to children’s vaccination status. The author of the post claims a recent...
Hippocratic AI Expands Footprint, Partners with Leading Health Systems to Improve Patient Outcomes
Hippocratic AI announced new collaborations with Cincinnati Children’s, UNC Health and the Gift of Life Marrow Registry, extending its safety‑first generative AI tools across pediatrics, primary‑care scheduling and donor outreach. The company’s AI Front Door and Nurse Co‑Pilot are now...
![His Mother-in-Law Heard “Cancer,” Went Home, and Was Dead Within a Year [PODCAST]](/cdn-cgi/image/width=1200,quality=75,format=auto,fit=cover/https://kevinmd.com/wp-content/uploads/Design-1-1-scaled.jpg)
His Mother-in-Law Heard “Cancer,” Went Home, and Was Dead Within a Year [PODCAST]
Alan P. Feren, a retired surgeon and patient advocate, discusses the concept of “unfinishedness” in medicine—where clinicians achieve administrative closure but leave patients without clear clinical reasoning. He illustrates the issue with his mother‑in‑law’s early chronic lymphocytic leukemia diagnosis, where she...
EXPOSED: One in Seven Vaccinated People Report Serious Adverse Events — And the Cover-Up Continues
A UK Medicines and Healthcare products Regulatory Agency (MHRA) active‑surveillance study of 30,281 COVID‑vaccine recipients reported that 13.7% experienced medically serious adverse events, while over half reported any reaction. The data, collected between 2020 and 2022, were released only in...
Liquid Metal Nanoparticles Freeze Into Spikes that Kill Drug-Resistant Cancer
Researchers have engineered bismuth‑doped gallium liquid‑metal nanoparticles that become spiky during freezing, puncturing cancer cells and killing drug‑resistant lung, colorectal and ovarian tumor organoids. The alloy reduces supercooling, raising the fraction of deformable particles from 2% to roughly 10% and...
Why Health Care Fraud Detection Requires Payment Integrity Alignment
Health care organizations are grappling with a structural split between payment integrity (PI) teams and special investigations units (SIU), which often review the same providers with divergent conclusions. While PI focuses on claim accuracy, SIU hunts for fraudulent intent, leading...
How Advances in Chronic Lymphocytic Leukemia Medications Are Shaping Patient Care Protocols
Over the past decade, chronic lymphocytic leukemia (CLL) treatment has shifted from broad chemotherapy to targeted, oral therapies such as BTK and BCL‑2 inhibitors, monoclonal antibodies, and personalized regimens based on genetic profiling. These drugs deliver higher response rates, longer...
The Hidden Dangers of Dental Sedation and Dental Anesthesia in Kids
An 4‑year‑old died after office‑based dental sedation when oxygen levels fell and the child became brain‑dead, highlighting the hidden dangers of pediatric dental anesthesia. The article notes that most anesthesia‑related deaths in office settings involve children aged 2‑5 and are...
Sunnybrook Announces $41-Million Gift to Advance Canada’s Global Leadership in Clinical Trials
Sunnybrook Health Sciences Centre announced a $41 million CAD (≈$30 million USD) philanthropic gift to expand its Sunnybrook Clinical Trials program. The funding creates new leadership positions, boosts biobanking, data management and precision diagnostics, and supports first‑time investigators. By strengthening infrastructure and...
Flash Drives and Funny Numbers: What Elevance Health’s Earnings Really Reveal
Elevance Health posted Q1 adjusted earnings of $12.58 per share, surpassing analysts' forecasts and lifted its full‑year adjusted EPS outlook. The company simultaneously disclosed a $935 million charge representing its best estimate of potential Medicare Advantage overpayments tied to seven years...
Pharmaceutical Executive Daily: FDA Issues CRL to AbbVie
The U.S. Food and Drug Administration issued a complete response letter to AbbVie, rejecting its biologics license application for trenibotulinumtoxinE due to manufacturing and CMC deficiencies. The setback delays AbbVie’s entry into the lucrative neurotoxin market, a segment dominated by...
Why Your Tortillas Now Have Folic Acid (And Why That Matters for Latina Health)
On Jan 1 2026 California enacted a law requiring folic acid fortification of all commercially produced corn masa products, including tortillas. The measure targets the higher incidence of neural‑tube defects among Latina births, a gap left by earlier grain‑fortification policies that excluded...
BROKE: Mills Quietly Freezes MaineCare Provider Payments Until July 1 as Fraud Probes Close In
Governor Janet Mills’ Department of Health and Human Services has again frozen MaineCare provider payments, postponing pharmacy claims from mid‑May through June 30 until the start of the new fiscal year on July 1. The delay follows a supplemental budget that...
Friday Subscriber Discussion - Action!
The Friday Subscriber Discussion post invites readers to brainstorm actionable steps for reducing institutional weight stigma. It highlights everyday barriers, such as non‑armless chairs in waiting rooms, and encourages community members to share practical suggestions. The author frames the conversation...
Building a Better Delivery System for Gene Editing Machines by Re-Engineering the Cellular Factory
A genome‑wide knockout screen conducted by the Whitehead Institute revealed specific producer‑cell genes that govern the assembly and potency of virus‑like particles (VLPs) used for gene‑editing delivery. Disabling a single brake gene dramatically increased guide‑RNA loading, boosting particle potency across...
ChatGPT for Clinicians: The Trap Sprung
OpenAI unveiled ChatGPT for Clinicians, a free GPT‑5.4‑powered assistant for verified U.S. physicians, nurse practitioners, physician assistants and pharmacists. The tool offers peer‑reviewed literature search, reusable workflow templates such as referral letters and prior authorizations, deep journal research, and built‑in...
Secretary Kennedy’s Eight Major Health Policy Wins to Date
HHS Secretary Ryan Kennedy has highlighted eight major health policy achievements since his February confirmation, ranging from drug‑price reductions to new dietary guidelines. The Trump RX website now lets consumers purchase prescription drugs directly from manufacturers at lower costs, while the 2024...
5 Patterns Behind Health Care Startups that Fail
Health‑care startups often fail not because of weak technology but due to strategic missteps. Dr. Harsha Moole identifies five recurring patterns: solving conference‑level problems instead of bedside needs, building products without knowing the true buyer, mistaking FDA clearance for market...
LogiPharma Europe: A New Model for Cold Chain Decision-Making
At LogiPharma Europe 2026, Roche’s global head of Distribution Technology, Raquel Vazquez, outlined a shift from experience‑based to data‑driven cold‑chain decision‑making. She highlighted the need to contextualize fragmented sensor data across lanes, products and environmental conditions to select the right packaging...
Highly Credentialed Health Experts Made Completely Insane, Debunked Claims About COVID Vaccines
The blog argues that highly credentialed health experts repeatedly issued misleading statements about COVID‑19, from flip‑flopping on mask mandates to overstating vaccine ability to halt infection and transmission. It cites a study by a credentialed group that alleges these experts...
Rethinking Nutrition Policy on Ultra-Processed Food
A new review challenges the blanket vilification of ultra‑processed foods, showing that health risk varies by sub‑category rather than processing alone. Processed meats, sugary and artificially sweetened drinks, and certain fats consistently raise cardiometabolic risk, while whole‑grain breads, cereals, and...
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign
Genentech, part of the Roche Group, launched the "All Eyes on DME" campaign to raise awareness of diabetic macular edema (DME) using humor and personal stories. The initiative partners with comedian Damon Wayans, who lives with type 2 diabetes, and advocacy...
Lantern Pharma to Debut Public Demonstration of withZeta.ai – A Platform to Conquer Rare Cancers on April 30 Following AACR...
Lantern Pharma announced a public, unscripted demonstration of its withZeta.ai AI co‑scientist platform on April 30, 2026. CEO Panna Sharma will lead two live sessions—morning and afternoon ET—to showcase real‑time drug‑discovery workflows for rare cancers. The event follows the platform’s...
Beyond Tools: Joydeep Ganguly on Building End-to-End 4IR Supply Chains
Pharma supply chains are hitting a complexity inflection point, with DSCSA enforcement and the rise of temperature‑sensitive therapies demanding tighter visibility and traceability. Joydeep Ganguly, Agilent’s chief operations and quality officer, told LogiPharma Europe 2026 that successful 4IR adoption starts with a...
No More Flu Shot Mandate… Now What?
The U.S. military has lifted its universal flu‑shot mandate, ending a policy that has existed since the Revolutionary War. The change signals a shift toward greater respect for individual autonomy and informed consent, even in a highly communal environment. While...
Bristol Myers Squibb and Pfizer to Make Eliquis® (Apixaban) Available via Mark Cuban Cost Plus Drug Company
Bristol Myers Squibb and Pfizer announced that their joint‑venture will sell Eliquis® (apixaban) through Mark Cuban’s Cost Plus Drugs platform starting April 27, 2026. Cash‑pay patients can purchase a 30‑day supply for $345, a price positioned below many insurance copays. The move expands the...
Pharma & Biotech Patent Litigation in Europe Conference Returns with IPKat Readers’ Discount
The Pharma & Biotech Patent Litigation in Europe conference returns for a two‑day session in central Amsterdam. Organisers highlight a special 10% discount for IPKat readers using code D10‑999‑IPKAT26. The agenda tackles hot topics such as cross‑border enforcement after the...